CGP-35269

N/A

Report date: 2022/01/24 13:25:22

Base Information

Drug NameCGP-35269

Drug Alias NamerHu INF-alpha B/D hybridInterferon-alpha B/D hybridInterferon-alpha-1/alpha-8 hybridRecombinant human interferon-alpha B/D hybridIFNα B/D +[6]

ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines

Mechanisms of ActionInterferon alpha/beta receptor agonists

TargetsInterferon alpha/beta receptor

Therapy Area/IndicationsHepatitis BHIV Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNovartis Pharma Ag

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNovartis Pharma Ag

Active IndicationsN/A

Inactive IndicationsHepatitis BHIV Infections

Other Information

ATC CodeN/A